Conditional survival and changing risk profile in patients with gliosarcoma.

conditional survival gliosarcoma nomogram prognosis risk stratification

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2024
Historique:
received: 03 06 2024
accepted: 28 08 2024
medline: 23 9 2024
pubmed: 23 9 2024
entrez: 23 9 2024
Statut: epublish

Résumé

Conditional survival (CS) considers the duration since the initial diagnosis and can provide supplementary informative insights. Our objective was to evaluate CS among gliosarcoma (GSM) patients and develop a CS-incorporated nomogram to predict the conditional probability of survival. This retrospective study using the Surveillance, Epidemiology, and End Results (SEER) database included patients with GSM between 2000 and 2017. The CS was defined as the probability of surviving additional y years after already surviving for x years. The formula utilized for CS was: CS(y|x) = S(y + x)/S(x), where S(x) denotes the overall survival at x years. Univariate Cox regression, best subset regression (BSR) and the least absolute shrinkage and selection operator (LASSO) were used for significant prognostic factors screening. Following this, backward stepwise multivariable Cox regression was utilized to refine predictor selection. Finally, a novel CS-integrated nomogram model was developed and we also employed diverse evaluation methods to assess its performance. This study included a total of 1,015 GSM patients, comprising 710 patients in training cohort and 305 patients in validation cohort. CS analysis indicated a gradual increase in the probability of achieving a 5-year survival, ascending from 5% at diagnosis to 13, 31, 56, and 74% with each subsequent year survived after 1, 2, 3, and 4 years post-diagnosis, respectively. Following variable screening through univariate Cox regression, BSR, and LASSO analysis, five factors-age, tumor stage, tumor size, radiotherapy, and chemotherapy-were ultimately identified for constructing the CS-nomogram model. The performance of the nomogram model was validated through discrimination and calibration assessments in both the training and validation cohorts. Furthermore, we confirmed that the effectiveness of the CS-nomogram in stratifying GSM patient risk status. This nationwide study delineated the CS of patients diagnosed with GSM. Utilizing national data, a CS-nomogram could provide valuable guidance for patient counseling during follow-up and risk stratification.

Sections du résumé

Background UNASSIGNED
Conditional survival (CS) considers the duration since the initial diagnosis and can provide supplementary informative insights. Our objective was to evaluate CS among gliosarcoma (GSM) patients and develop a CS-incorporated nomogram to predict the conditional probability of survival.
Methods UNASSIGNED
This retrospective study using the Surveillance, Epidemiology, and End Results (SEER) database included patients with GSM between 2000 and 2017. The CS was defined as the probability of surviving additional y years after already surviving for x years. The formula utilized for CS was: CS(y|x) = S(y + x)/S(x), where S(x) denotes the overall survival at x years. Univariate Cox regression, best subset regression (BSR) and the least absolute shrinkage and selection operator (LASSO) were used for significant prognostic factors screening. Following this, backward stepwise multivariable Cox regression was utilized to refine predictor selection. Finally, a novel CS-integrated nomogram model was developed and we also employed diverse evaluation methods to assess its performance.
Results UNASSIGNED
This study included a total of 1,015 GSM patients, comprising 710 patients in training cohort and 305 patients in validation cohort. CS analysis indicated a gradual increase in the probability of achieving a 5-year survival, ascending from 5% at diagnosis to 13, 31, 56, and 74% with each subsequent year survived after 1, 2, 3, and 4 years post-diagnosis, respectively. Following variable screening through univariate Cox regression, BSR, and LASSO analysis, five factors-age, tumor stage, tumor size, radiotherapy, and chemotherapy-were ultimately identified for constructing the CS-nomogram model. The performance of the nomogram model was validated through discrimination and calibration assessments in both the training and validation cohorts. Furthermore, we confirmed that the effectiveness of the CS-nomogram in stratifying GSM patient risk status.
Conclusion UNASSIGNED
This nationwide study delineated the CS of patients diagnosed with GSM. Utilizing national data, a CS-nomogram could provide valuable guidance for patient counseling during follow-up and risk stratification.

Identifiants

pubmed: 39309681
doi: 10.3389/fmed.2024.1443157
pmc: PMC11412853
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1443157

Informations de copyright

Copyright © 2024 Xu, Yang, Chen, Sun, Tu, Gu and Luo.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Lei Xu (L)

Department of Neurosurgery, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Shaoxing, China.

Zhihao Yang (Z)

Department of Neurosurgery, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Shaoxing, China.

Huawei Chen (H)

Department of Neurosurgery, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Shaoxing, China.

Chengjun Sun (C)

Department of Neurosurgery, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Shaoxing, China.

Chuanjian Tu (C)

Department of Neurosurgery, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Shaoxing, China.

Zhiwei Gu (Z)

Department of Neurosurgery, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Shaoxing, China.

Ming Luo (M)

Department of Neurosurgery, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Shaoxing, China.

Classifications MeSH